Mustering hope in the obesity space – marked by drugs' generally disappointing sales despite a large and growing market – is tough, but Boston-based Zafgen Inc. recently drew investor enthusiasm and pulled off a $138 million public offering to advance what RBC Capital Markets analyst Simos Simeonidis called "a really impressive drug."